Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Chunlizhengda Medical Instruments Co., Ltd. (688236.SS)
Beijing, CN
Beijing Chunlizhengda Medical Instruments Co., Ltd. operates as a specialist in orthopedic medical devices. Its core activities encompass the development, manufacturing, and marketing of surgical implants, instruments, and related medical supplies. While primarily focused on the People's Republic of China, its product portfolio prominently features implantable orthopedic solutions, particularly artificial joint prostheses and spinal systems. The company distributes its offerings mainly through a network of channel partners, engages in ODM/OEM collaborations, and supplies hospitals directly, all under its established Chunli brand. Additionally, Beijing Chunlizhengda extends its reach by exporting products to various international markets. Established in 1998, the firm maintains its headquarters in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.62% | -2.17% | -14.30% | -20.61% | -37.29% | -23.25% | +15.60% | -47.61% | -38.64% | -38.64% | -38.64% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+29.5% ★ Q1'26: -5.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+115.2% ★ Q1'26: +6.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+31.9% Q1'26: -14.3% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+28.9% ★ Q1'26: +29.0% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+35.4% ★ Q1'26: +24.2% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+1.2% Q1'26: -1.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.01× ★ Q1'26: 0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
177.37M
est: 202.00M (-12.2%)
|
207.93M
est: 197.00M (+5.5%)
|
300.32M
est: 254.00M (+18.2%)
|
497.93M
est: 456.00M (+9.2%)
|
855.33M
est: 912.32M (-6.2%)
|
937.69M
est: 984.00M (-4.7%)
|
1.11B
est: 1.22B (-9.1%)
|
1.20B
est: 1.20B (0.0%)
|
1.21B
est: 1.27B (-4.9%)
|
805.86M
est: 775.00M (+4.0%)
|
1.04B
est: 1.13B (-7.5%)
|
1.32B
1.32B – 1.32B
+17.2% YoY
|
1.62B
1.62B – 1.62B
+22.1% YoY
|
1.81B
1.81B – 1.81B
+12.1% YoY
|
| EBITDA |
48.45M
est: 54.28M (-10.7%)
|
79.81M
est: 52.93M (+50.8%)
|
85.39M
est: 68.25M (+25.1%)
|
126.96M
est: 122.52M (+3.6%)
|
284.92M
est: 245.13M (+16.2%)
|
344.93M
est: 264.39M (+30.5%)
|
384.18M
est: 327.54M (+17.3%)
|
365.26M
est: 322.97M (+13.1%)
|
339.52M
est: 341.42M (-0.6%)
|
169.04M
est: 227.05M (-25.6%)
|
337.63M
est: 330.63M (+2.1%)
|
387.60M
387.60M – 387.60M
+17.2% YoY
|
473.24M
473.24M – 473.24M
+22.1% YoY
|
530.27M
530.27M – 530.27M
+12.1% YoY
|
| EBIT |
43.59M
est: 49.15M (-11.3%)
|
73.81M
est: 47.93M (+54.0%)
|
78.88M
est: 61.80M (+27.6%)
|
119.55M
est: 110.94M (+7.8%)
|
273.13M
est: 221.96M (+23.0%)
|
329.99M
est: 239.40M (+37.8%)
|
367.64M
est: 296.58M (+24.0%)
|
337.13M
est: 292.44M (+15.3%)
|
306.27M
est: 309.15M (-0.9%)
|
132.63M
est: 204.43M (-35.1%)
|
301.22M
est: 297.69M (+1.2%)
|
348.99M
348.99M – 348.99M
+17.2% YoY
|
426.10M
426.10M – 426.10M
+22.1% YoY
|
477.45M
477.45M – 477.45M
+12.1% YoY
|
| Net Income |
37.87M
est: 57.33M (-33.9%)
|
63.44M
est: 66.59M (-4.7%)
|
68.28M
est: 92.84M (-26.5%)
|
105.65M
est: 110.98M (-4.8%)
|
236.76M
est: 279.04M (-15.2%)
|
283.37M
est: 298.51M (-5.1%)
|
322.36M
est: 375.05M (-14.0%)
|
307.72M
est: 302.33M (+1.8%)
|
277.82M
est: 279.37M (-0.6%)
|
124.99M
est: 118.81M (+5.2%)
|
272.12M
est: 258.71M (+5.2%)
|
328.34M
328.34M – 328.34M
+26.9% YoY
|
402.44M
402.44M – 402.44M
+22.6% YoY
|
494.42M
494.42M – 494.42M
+22.9% YoY
|
| SGA |
81.50M
est: 68.39M (+19.2%)
|
87.34M
est: 66.70M (+30.9%)
|
112.06M
est: 86.00M (+30.3%)
|
162.22M
est: 154.40M (+5.1%)
|
249.36M
est: 308.90M (-19.3%)
|
272.23M
est: 333.17M (-18.3%)
|
372.73M
est: 412.74M (-9.7%)
|
430.31M
est: 406.98M (+5.7%)
|
427.61M
est: 430.23M (-0.6%)
|
285.54M
est: 237.89M (+20.0%)
|
137.91M
est: 346.41M (-60.2%)
|
406.09M
406.09M – 406.09M
+17.2% YoY
|
495.83M
495.83M – 495.83M
+22.1% YoY
|
555.58M
555.58M – 555.58M
+12.1% YoY
|
| EPS |
0.12
est: 0.15 (-19.9%)
|
0.18
est: 0.17 (+3.4%)
|
0.20
est: 0.24 (-17.6%)
|
0.30
est: 0.29 (+3.4%)
|
0.68
est: 0.73 (-6.7%)
|
0.82
est: 0.78 (+5.1%)
|
0.93
est: 0.98 (-5.1%)
|
0.80
est: 0.79 (+1.3%)
|
0.72
est: 0.73 (-1.4%)
|
0.33
est: 0.31 (+6.5%)
|
0.71
est: 0.68 (+5.2%)
|
0.86
0.86 – 0.86
+26.9% YoY
|
1.05
1.05 – 1.05
+22.6% YoY
|
1.29
1.29 – 1.29
+22.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 4/5 | 2/5 | 3/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chunbao Shi | Chief Engineer & Executive Director | 1M | male |
| Shujun Yue | Deputy GM & Executive Director | 897.7K | female |
| Feng Bao Xie | Deputy Chief Engineer, Secretary of the Board & Executive Director | 354.4K | male |
| Wenling Shi | Executive Chair of the Board | 341.1K | female |
| Hongyue Lu | Chief Financial Officer | — | female |
| Chunsheng Shi | General Manager | — | male |
| Xiwang Li | Deputy General Manager | — | male |
| Zhiyong Zhai | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688236.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
